About Arbutus Biopharma Corporation
Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company’s research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients’ HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania. Address: 701 Veterans Circle, Warminster, PA, United States, 18974
Arbutus Biopharma Corporation News and around…
Latest news about Arbutus Biopharma Corporation (ABUS) common stock and company :
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...
ABUS earnings call for the period ending June 30, 2022.
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus AstraZeneca/Merck's ...
Arbutus (ABUS) delivered earnings and revenue surprises of 23.08% and 165.39%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Arbutus Biopharma (NASDAQ:ABUS) reported its Q2 earnings results on Thursday, August 4, 2022 at 07:30 AM. Here's what ...
Key milestones across our chronic hepatitis B virus (cHBV) and pan-coronavirus programs remain on track Financially strong with a projected cash runway into the second quarter of 2024 Conference Call and Webcast Today at 8:45 AM ET WARMINSTER, Pa., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today reports its
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Verve Therapeutics, Vertex ...
WARMINSTER, Pa., July 21, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that it has scheduled its second quarter 2022 financial results and corporate update for Thursday, August 4, 2022. The schedule for the press release and conference call/webcast are as follows: •Q2/2022 Press Release:Thursday, August
Triple combination clinical trial evaluating AB-729, an RNAi therapeutic, vebicorvir, Assembly Biosciences’ core inhibitor, and nucleos(t)ide analog continues with data expected in 2H 2022 WARMINSTER, Pa., July 20, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that while its partner, Assembly Biosciences
Arbutus (ABUS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
JMP Securitiesreiterates its Market Outperform rating but reduces theprice target to $9 from $10onArbutus ...
AB-729, our RNAi therapeutic, provided robust and comparable HBsAg declines in both HBeAg+ and HBeAg- patients 50% (16 out of 32) of patients maintained HBsAg levels below 100 IU/mL 24 weeks after their last AB-729 dose In the first five patients who discontinued both AB-729 and NA therapy after meeting stopping criteria, there has been no evidence of virologic or clinical relapse in 8-24 weeks of follow-up Preliminary data to date have shown that AB-729 remains generally safe and well-tolerated
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Vanguard Russell 2000 ETF (VTWO), we found that the implied analyst target price for the ETF based upon its underlying holdings is $99.99 per unit.
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ETWARMINSTER, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that seven abstracts have been accepted for poster presentations at the European Association for the Study of the
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although...
Trial will evaluate AB-729, an RNAi therapy in combination with VTP-300, an immunotherapeutic, and NA therapyWARMINSTER, Pa. and OXFORD, United Kingdom, June 06, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, and Vaccitech plc (Nasdaq: VACC), a clinical-stage biopharmaceutical company engaged in the discovery and develop
WARMINSTER, Pa., June 02, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that the Company will participate in the following upcoming investor conferences taking place in New York: Jefferies Healthcare Conference (June 8 - 10, 2022) Fireside Chat: 3:00 pm ET on Thursday, June 9, 2022Presenters: Michael McE
WARMINSTER, Pa., May 26, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that its abstract on a preclinical oncology study for one of Arbutus’ oral PD-L1 inhibitor compounds designed to reawaken the immune system, has been selected for publication at the American Society of Clinical Oncology (ASCO) Annual
The Pennsylvania Biotechnology Center of Bucks County and its affiliated organizations have generated an economic impact of $7.3 billion for the state during the past six years, according to a new study. The analysis, conducted by KLIOS Consulting economist Richard M. Stein, found that between the beginning of 2016 and the end of 2021, the biotech center produced a $2.3 billion direct impact tied to spending and economic activity at the center, and another $3.5 billion in indirect spending elsewhere in Pennsylvania tied to initial economic activity at the center. The remaining $1.5 billion represents the center's "induced impact," which is economic benefit related to additional household spending created from biotech center activities and related indirect economic activity.
WARMINSTER, Pa., May 17, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics that target specific viral diseases, today announced that William Collier, Arbutus’ President and Chief Executive Officer, will present at the H.C. Wainwright Global Investment Conference on Tuesday, May 24, 2022, at 11:30 am ET in Miami, FL. A live webcast of the presentation can be ac
CNBC Ford Motor Selling 8M Shares Of Rivian Automotive Ford Motor Company(NYSE:F) will sell 8 millionRivian ...
Moderna Inc(NASDAQ: MRNA) is trying to fight off rival companies’ patent infringement claims related to its COVID-19 ...
Arbutus Biopharma Corporation ( NASDAQ:ABUS ) shareholders will have a reason to smile today, with the analysts making...
ABUS earnings call for the period ending March 31, 2022.
Arbutus Biopharma (NASDAQ:ABUS) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:30 AM. Here's what ...
Arbutus (ABUS) delivered earnings and revenue surprises of 15.38% and 118.16%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus FDA Approval For ...
Arbutus Biopharma (NASDAQ:ABUS) will host a conference call at 08:45 AM ET on May 5, 2022, to discuss Q1 2022 earnings ...
Investors in Arbutus Biopharma Corp (ABUS) saw new options become available this week, for the December 16th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..
Canada-basedAcuitas Therapeutics Inchas suedArbutus Biopharma Corporation(NASDAQ: ABUS) in Manhattan federal ...
Arbutus Biopharma Corporation (ABUS) is a NASDAQ Common Stock listed in Biotechnology, Common Stock, Healthcare
